An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having C.sub.max to C.sub.min ratio less than 200 and lag time less than 0.2.

A radioactive thermogel suspension, including a thermogel and a plurality of insoluble radioactive isotope phosphate particles, such as yttrium phosphate, suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03.Math.m and 10.Math.m in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

In some aspects, the present disclosure pertains to a polymer that comprises a plurality of polymer arms, wherein a first portion of the polymer arms comprise a reactive end group and wherein a second portion of the polymer arms comprise a branched end group that comprise a plurality of covalently attached diagnostic and/or therapeutic groups, which may be, for example, radiocontrast groups or radioactive groups. Other aspects pertain to a system that comprises (a) a first composition comprising such a polymer and (b) a second composition comprising a multifunctional compound that comprises reactive functional groups that are reactive with the reactive end group of the multi-arm polymer. Still other aspects pertain to a crosslinked reaction product of (a) such a polymer and (b) a multifunctional compound that comprises functional groups that are reactive with the reactive end group of the multi-arm polymer.

The invention comprises a method of making a mineral plant nutrient. The method comprises screening or reducing in size basaltic hyaloclastite or intermediate basaltic hyaloclastite to a powder form having volume-based mean particle size of less than or equal to 100 m; and combining the basaltic hyaloclastite or intermediate hyaloclastite powder with soil. The plant nutrients are absorbed by the crop and the carbonatable minerals released from the hyaloclastite react with CO.sub.2 from the ground and air. Elements weathered into the separate plant nutrients and carbonatable elements. Plant nutrients such as K, P, S, B, Co, Cu, Fe, Mo, Zn and Ni are used by the crop plants as nutrients. Carbonatable elements such as Ca, Mg, K, Na and Fe react with CO.sub.2 from the hyaloclastite, in the ground and the air to create simple or complex carbonated mineral, thereby mineralizing CO.sub.2 Optionally, the hyaloclastite can be substituted with lava, scoria, volcanic ash or pumice containing carbonatable elements that when dissolved in soil can react with CO.sub.2 and create simple or complex carbonate minerals thereby mineralizing or sequestrating CO.sub.2

The present invention provides peptide hydrogelators capable of forming hydrogels as carriers of active ingredients and acting as sustained or controlled release drug delivery systems.

The present invention relates to alginate-based gels for use in radiotherapy. More particularly, the invention provides an alginate gel comprising a peptide-coupled alginate, at least one type of divalent cation, and at least one radionuclide cation; a method for providing at least one alginate gel particle; a composition comprising said alginate gel; said alginate gel or composition for use as a medicament; said alginate gel or composition for use in a method for the treatment of a proliferative disease; and kits comprising an alginate and a radionuclide cation.

The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing the compositions, as well as methods of using the same.

A starch-based injectable hydrogel system for localized cancer treatment. The pre-formed hydrogel delivers chemotherapeutic drugs (such as doxorubicin) and/or medical radionuclides directly to tumor sites while minimizing systemic exposure. The composition uses dimethyl sulfoxide as a solvent and can be stored in pre-filled syringes for clinical use. Key advantages include >90% drug retention, sustained local delivery, and compatibility with image-guided injection techniques. The system is particularly suitable for pediatric brain tumors and other solid tumors requiring localized high-dose therapy.